Evidence map›Paper›PMID 31007971›Full record

ArticleClinical pharmacology & biopharmaceutics2017

A 2-year Double-Blind RCT Follow-up Study with Fermented Papaya Preparation (FPP) Modulating Key Markers in Middle-Age Subjects with Clustered Neurodegenerative Disease-Risk Factors.

Francesco Marotta, Massimiliano Marcellino, Umberto Solimene, Biagio Cuffari, Hariom Yadav, Alexander N Khokhlov, Aldo Lorenzetti, Amelie Mantello, Joseph Cervi, Roberto Catanzaro

Open access · greenAbstract read
In one paragraph

Article in Clinical pharmacology & biopharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Beneficial Effects of Fermented Papaya Preparation (FPPAntioxidants (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Francesco MarottaReGenera Research Group for Aging Intervention, San Babila Clinic, Milano, Italy.
Massimiliano MarcellinoReGenera Research Group for Aging Intervention, San Babila Clinic, Milano, Italy.
Umberto SolimeneWHO-Center for Traditional Medicine and Biotechnology, University of Milano, Italy.
Biagio CuffariDepartment of Internal Medicine, University of Catania, Catania, Italy.
Hariom YadavCenter for Diabetes, Obesity and Metabolism, Wake Forest Medical Center, Biotech Place, Winston-Salem, USA.
Alexander N KhokhlovEvolutionary Cytogerontology Sector, School of Biology, Moscow State University, Moscow, Russia.
Aldo LorenzettiReGenera Research Group for Aging Intervention, San Babila Clinic, Milano, Italy.
Amelie MantelloOsato Research Institute and Labs, Gifu, Japan.
Joseph CerviReGenera Research Group for Aging Intervention, San Babila Clinic, Milano, Italy.
Roberto CatanzaroDepartment of Internal Medicine, University of Catania, Catania, Italy.
University of Catania · ITLomonosov Moscow State University · RU

Funding

Intramural NIH HHS Z99 DK999999
6 · The paper itself

Abstract

In recent years a number of studies have reported the significant relationship between metabolic syndrome and neurodegenerative disease. There is accumulating evidence that the interplay of combined genetic and environmental risk factors (from diet to life style to pollutants) to intrinsic age-related oxi-inflammatory changes may be advocated for to explain the pandemic of neurodegenerative diseases. In recent years a specific Fermented Papaya Preparation (FPP) has been shown to significantly affect a number of redox signalling abnormalities in a variety of chronic diseases and as well in aging mechanisms either on experimental and on clinical ground. The aim of the present study was to evaluate FPP use in impending metabolic disease patients with potentially neurodegenerative disease clustered risk factors. The study population consisted of 90 patients aged 45-65 years old, with impending metabolic syndrome and previously selected as to be ApoE4 genotype negative. By applying a RCT, double-blind method, one group received FPP 4.5 g twice a day (the most common dosage utilized in prior clinical studies) while the other received an oral antioxidant cocktail (trans-resveratrol, selenium, vitamin E, vitamin C). Then, after 21 month treatment period, a selected heavy metal chelator was added at the dosage of 3 g/nocte for the final 3 months study treatment. The parameters tested were: routine tests oxidized LDL-cholesterol, anti-oxidised LDL, Cyclophilin-A (CyPA), plasminogen activator inhibitor-1 and CyPA gene expression. From this study it would appear that FPP, unlike the control antioxidant, significantly decreased oxidized-LDL and near normalizing the anti-Ox-LDL/Ox-LDL ratio (p<0.001) although unaffecting the lipid profile

Indexed as

AntioxidantCaviarlieriFermented Papaya Preparation (FPP)Neurodegenerative diseaseRedox balance

Identifiers

PMID31007971
PMCPMC6474671
OpenAlexW2622786736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.